Intravenous administration of ferric derisomaltose is associated with a higher incidence of infusion reactions than ferric carboxymaltose, and unaffected by dilution volume.

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Sarah Lucas, Ayushi Chauhan, Ciaran Hurley, Calvin Xu, Catherine Yu, Katrina Tan, Sarah Taylor, Mani Suleiman, Teresa Leung, Mayur Garg
{"title":"Intravenous administration of ferric derisomaltose is associated with a higher incidence of infusion reactions than ferric carboxymaltose, and unaffected by dilution volume.","authors":"Sarah Lucas, Ayushi Chauhan, Ciaran Hurley, Calvin Xu, Catherine Yu, Katrina Tan, Sarah Taylor, Mani Suleiman, Teresa Leung, Mayur Garg","doi":"10.1111/imj.70100","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The incidence of and risk factors for infusion-related reactions to intravenous iron formulations remains poorly characterised. This study aimed to compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.</p><p><strong>Aims: </strong>To compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.</p><p><strong>Methods: </strong>This was a single tertiary centre retrospective matched cohort study of patients who received FDI or FCM between January 2022 and May 2023. Reactions were classified as Fishbane or hypersensitivity and characterised by severity using the Ring and Messmer classification.</p><p><strong>Results: </strong>A total of 660 patients (330 age- and sex-matched patients who received FDI and FCM, respectively) were included. Hypersensitivity reactions occurred in 34 of 330 (10.3%) patients receiving FDI infusions compared to eight of 330 (2.4%) patients receiving FCM (odds ratio (OR), 4.62 (95% confidence interval (CI), 2.10-9.78), P < 0.0001). All reactions to FCM and FDI were classified as mild to moderate except for one grade III reaction to FDI. There was no difference in the rate of reaction between patients receiving FDI diluted in 100 mL (18/165) compared to 250 mL (16/165) sodium chloride (OR, 1.14 (95% CI, 0.55-2.27), P = 0.86). A history of a reaction to an alternative iron formulation was associated with increased risk of infusion reactions (OR, 3.55 (95% CI, 0.67-18.97), P = 0.14) and increasing age was associated with reduced risk (OR, 0.96 (95% CI, 0.94-0.99), P = 0.02).</p><p><strong>Conclusion: </strong>Patients receiving FDI had a significantly higher risk of mild infusion reactions compared to those receiving FCM, with no difference across different dilution volumes of FDI.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.70100","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The incidence of and risk factors for infusion-related reactions to intravenous iron formulations remains poorly characterised. This study aimed to compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.

Aims: To compare the rates of infusion reactions in patients receiving ferric derisomaltose (FDI) compared to ferric carboxymaltose (FCM), as well as across different dilutions of FDI.

Methods: This was a single tertiary centre retrospective matched cohort study of patients who received FDI or FCM between January 2022 and May 2023. Reactions were classified as Fishbane or hypersensitivity and characterised by severity using the Ring and Messmer classification.

Results: A total of 660 patients (330 age- and sex-matched patients who received FDI and FCM, respectively) were included. Hypersensitivity reactions occurred in 34 of 330 (10.3%) patients receiving FDI infusions compared to eight of 330 (2.4%) patients receiving FCM (odds ratio (OR), 4.62 (95% confidence interval (CI), 2.10-9.78), P < 0.0001). All reactions to FCM and FDI were classified as mild to moderate except for one grade III reaction to FDI. There was no difference in the rate of reaction between patients receiving FDI diluted in 100 mL (18/165) compared to 250 mL (16/165) sodium chloride (OR, 1.14 (95% CI, 0.55-2.27), P = 0.86). A history of a reaction to an alternative iron formulation was associated with increased risk of infusion reactions (OR, 3.55 (95% CI, 0.67-18.97), P = 0.14) and increasing age was associated with reduced risk (OR, 0.96 (95% CI, 0.94-0.99), P = 0.02).

Conclusion: Patients receiving FDI had a significantly higher risk of mild infusion reactions compared to those receiving FCM, with no difference across different dilution volumes of FDI.

静脉注射脱异麦芽糖铁比羧基麦芽糖铁有更高的输液反应发生率,且不受稀释量的影响。
背景:静脉铁制剂输注相关反应的发生率和危险因素的特征仍然很差。本研究旨在比较三异麦芽糖铁(FDI)与三羧基麦芽糖铁(FCM)患者的输注反应率,以及不同稀释度的FDI。目的:比较三异麦芽糖铁(FDI)与三羧基麦芽糖铁(FCM)患者的输液反应率,以及不同稀释度的FDI。方法:这是一项单三级中心回顾性匹配队列研究,研究对象是2022年1月至2023年5月期间接受FDI或FCM的患者。反应被分类为Fishbane或超敏反应,并以Ring和Messmer分类的严重程度为特征。结果:共纳入660例患者(330例年龄和性别匹配的患者分别接受FDI和FCM)。330例接受FDI输注的患者中有34例(10.3%)发生超敏反应,而330例接受FCM输注的患者中有8例(2.4%)发生超敏反应(优势比(OR)为4.62(95%可信区间(CI)为2.10-9.78),P结论:接受FDI的患者发生轻度输注反应的风险明显高于接受FCM的患者,不同稀释量的FDI没有差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信